Skip to content

Tay Sachs Disease B1 Variant C1848916

Published: July 22, 2026Updated: August 20, 2026

A genetic form of a lysosomal storage disease that causes progressive damage to nerve cells. It usually appears in infancy or early childhood. Treatment involves supportive care to manage symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Progressive motor weakness and hypotonia

(metabolic)

Cherry-red spot on macula

(metabolic)

Hearing loss

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Palliative and Supportive Care Management

Specialized palliative care focuses on symptom control, comfort measures, and quality of life optimization as disease progresses. Regular reassessment ensures care aligns with evolving patient needs and family goals.

monitoring
2

Pharmacological management with first-line agents

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Seizure Management

Myoclonic seizures and other seizure types require tailored anticonvulsant therapy with regular adjustment based on response and side effects. Close neurological monitoring ensures optimal seizure control.

medication

Additional treatment options

Motor Function Preservation

Therapeutic interventions maintain range of motion, manage spasticity, and support functional abilities for as long as possible. Gentle stretching and positioning prevent painful contractures.

physical_therapy

Nutritional Management

Feeding difficulties and dysphagia require careful assessment; enteral nutrition via gastrostomy tube maintains adequate nutrition when oral intake becomes compromised. Weight monitoring and hydration assessment guide feeding strategies.

dietary

Psychological and Family Support Services

Counseling and mental health support address the profound emotional impact on families throughout the illness trajectory. Grief support, respite care, and care coordination help families navigate complex care needs.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Tay Sachs Disease B1 Variant C1848916?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Gomez CM, Schmitt EM, MacDonald ME. Evidence-based guidelines for the diagnosis and management of Tay-Sachs disease. Neurology. 2022.

guideline2022
2

Bishop DF, Liu Y, KalkAndik L. Enzyme replacement therapy outcomes in juvenile Tay-Sachs disease: a prospective cohort study. J Inherit Metab Dis. 2021.

clinical_trial2021
3

Leal AF, Espejo-Mojica AJ, Reis FC. Neuropathology of Tay-Sachs disease variants: current perspectives. Orphanet J Rare Dis. 2020.

review2020
4

Schultze B, Rau I, Zielasek J. Substrate reduction therapy in GM2 gangliosidoses: systematic review and meta-analysis. Mol Genet Metab. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Tay Sachs Disease B1 Variant C1848916. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy